Combo Products Meeting Will Address Cross-Labeling, Dual Applications
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic ultrasound, magnetic resonance imaging and contrast agent companies will hold a series of meetings with FDA to address issues related to their respective device and drug premarket approvals
You may also be interested in...
CDRH Review Of Expanded Imaging Agent Indications Urged By NEMA
CDRH should serve as the lead reviewer for premarket applications of already-approved contrast agents indicated for use with diagnostic imaging devices, according to Philips Medical Systems VP-Quality & Regulatory Affairs Terry Sweeney
CDRH Review Of Expanded Imaging Agent Indications Urged By NEMA
CDRH should serve as the lead reviewer for premarket applications of already-approved contrast agents indicated for use with diagnostic imaging devices, according to Philips Medical Systems VP-Quality & Regulatory Affairs Terry Sweeney
Combo Products Collaborative, Consultative Review Document Outlines SOPs
FDA's interpretation of "primary mode of action," the principle underlying jurisdictional assignment of combination products, will be open for stakeholder comment during a second public meeting on the topic